# A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07659782/  
OnCo record `nct07659782` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of VS-7375 in non-small-cell lung cancer and small-cell lung cancer, run by Verastem, Inc., now recruiting.

## Summary

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07659782 by Verastem, Inc., with 105 participants planned, started 2026-07-22 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07659782
- Phase: 2
- Setting: A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)
- Sponsor: Verastem, Inc.
- Enrolled: 105

## Sources

- ClinicalTrials.gov NCT07659782: https://clinicaltrials.gov/study/NCT07659782

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [VS-7375](https://onco.cc/drugs/vs-7375/)
- companies: [Verastem Oncology](https://onco.cc/companies/verastem/)

---
JSON: https://onco.cc/api/v1/entities/nct07659782.json